Friday, October 23, 2026

CBOE Volatility Index Bearish Momentum: 3.62% Down Since The Last Session

ViaNews Editorial Team

January 8, 2021

CBOE Volatility Index Bearish Momentum: 3.62% Down Since The Last Session

CBOE Volatility Index is currently on bearish momentum. At 17:36 EST on Friday, 8 January, CBOE Volatility Index is at $21.56, 3.62% down since the last session's close.

CBOE Volatility Index Range

CBOE Volatility Index is 3.101% down from its last session low of $22.25 and 9.829% down from its last session high of $23.91.

Over the last three sessions, CBOE Volatility Index's higher value was $28.60 and the lower value was $22.14.

Over the last seven sessions, CBOE Volatility Index's higher value was $29.19 and the lower value was $20.99.

Over the last month, CBOE Volatility Index's higher value was $31.46 and the lower value was $20.10.

In relation to CBOE Volatility Index's yearly highs and lows, it's 83.489% up from its 52-week low and 74.775% down from its 52-week high.

Volatility

CBOE Volatility Index's last day, last week, and last month's average volatility was a negative 12.07%, a negative 0.22%, and a positive 0.32%, respectively.

CBOE Volatility Index's last day, last week, and last month's high and low average amplitude percentage was 7.46%, 16.51%, and 11.32%, respectively.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Crunch: Late-Stage Readouts and Regulatory Milestones Converge on the Ivonescimab PDUFA Date
October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,426 source documents archived
Query this data → isubstrate.com